Insilico Medicine, Inc. Announces Collaboration with Baseport Research Laboratories to …

BALTIMORE, Md., Aug. 18, 2015 (GLOBE NEWSWIRE) — via PRWEB – Insilico Medicine Inc., a company utilizing neural network based Deep Learning for drug discovery and repurposing targeting cancer and age-related diseases, announced it will be hosting the first commercial installation of miniature centi-terabyte scale desktop storage servers from BasePort Research Laboratories. The companies will collaborate on customizing the Linux based server software to optimize the system for the massive data storage and rapid retrieval requirements needed for Insilico Medicine’s investigations into clinical oncology, discovery and personalized medicine projects.

“Our current computational requirements exceed the levels achieved by supercomputers just a few years ago. With our recent collaboration with Nvidia, and installation and operation of its GPU based DevBox system, Insilico’s computational capabilities are ramping up to match these supercomputer levels. After searching the technically competitive genomics data storage market, we found that BasePort is best able to provide us with a matching level of scalable, energy and space efficient data storage, which also provides for extreme mobility. We are pleased to announce this collaboration as a demonstration of our continued leadership in this field,” said Alex Zhavoronkov, PhD, CEO of InSilico Medicine, Inc.

Insilico Medicine assembled one of the largest repositories of human multi-omics data, which includes genome, transcriptome, proteome and epigenome and metabolome data types mapped into unique pathway activation framework and linked to diseases, drugs and age-related pathologies. This data is used to train advanced deep neural nets to develop novel biomarkers and repurpose drugs. The minimum amount of information required for a training exercise is 40TB with a large amount of this information being proprietary and confidential data. Operating exclusively in a cloud can be expensive and far too slow due to the massive data transfer needed. To minimize costs and maximize performance, on-site storage is required. The tiny “shoe-box” sized form factor minimizes space intrusion into the office, and allows for unobtrusive installation of large multiples of data storage for expansion into the future.

“Next Generation Sequencing technology requires massive data storage, on a scale never seen before. The stackable BaseStation T80 and BaseStation T120 (80 & 120 raw terabyte) desktop systems deliver this capability to researchers and small clinics. The systems are office-quiet and extremely power efficient, processing at full capacity under 50 watts with all of the storage disks quiescent. For large installations, we are developing space and energy efficient 15 petabyte office friendly data storage towers. The huge, noisy, energy and cooling hungry rackmount systems of the past just don’t meet the current and future needs of the clinical office environment. We are very happy that our hardware meets Insilico’s exacting technical requirements and look forward to ongoing collaboration,” said Doug Fortune, CTO of BasePort Research Laboratories.

About InSilico Medicine

InSilico Medicine, Inc. is a Baltimore-based company utilizing advances in genomics and big data analysis for in silico drug discovery and drug repurposing targeting aging and age-related diseases. The company utilizes the GeroScope™, OncoFinder™, Pathway Cloud Intelligence™ and PharmAtlas™ platforms for aging and cancer research, pursues internal drug discovery programs, and provides services to pharmaceutical companies.

If you have any questions about the science of aging, bioinformatics, or InSilico Medicine’s plan in anti-aging research and drug discovery, please call (443) 451- 7212 or visit:

About BasePort Research

BasePort Research Laboratories is a Calgary, Canada-based high technology company dedicated to developing economical, scalable, extremely dense and energy efficient systems to support Next Generation Genomics data storage needs suitable for installation into typical clinical and office environments. The company’s website is

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit

InSilico Medicine, Inc.
Qingsong Zhu, PhD

+1 4434517212

Retrieved from “”

Source: Insilico Medicine, Inc. Announces Collaboration with Baseport Research Laboratories to …

Via: Google Alert for Deep Learning